Prices delayed by at least 15 minutes | Print
Avacta Group PLC (AVCT)
ORD 10POpen
65.00p
Previous close
64.00p
Trade high
68.00p
Volume
2,555,032
Year high
92.00p
Year low
48.00p
Dividend yield
–
Market capitalisation
£286.65 mn
P/E ratio
–
ISIN
GB00BYYW9G87
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Regular investment and Dividend reinvestment
Share price
Company profile
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessingits proprietary technology. Geographically, it derives revenue from South Korea.
News
Recent trades
| Date | Time | Price | Quantity | Value (£) |
|---|---|---|---|---|
| 09/10/2026 | 05:08:27 | 65.5 | 155,000 | 101,525.00 |
| 09/10/2026 | 04:35:26 | 65.5 | 5,448 | 3,568.44 |
| 09/10/2026 | 04:35:15 | 65.5 | 2,373 | 1,554.32 |
| 09/10/2026 | 04:29:58 | 64.2 | 65,870 | 42,288.54 |
| 09/10/2026 | 04:29:42 | 65.08 | 7,925 | 5,157.59 |